Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot microsphere platform for long-acting peptide formulations has not progressed to a commercial license despite nearly two years of joint research. The original October 2024 agreement was strictly non-binding, limited to internal feasibility testing of sustained-release microspheres for candidates including GLP-1 agonists, and explicitly allows Lilly to exit with 30 days’ notice. Lilly has pursued parallel long-acting delivery partnerships such as Camurus’ FluidCrystal technology and shifted emphasis toward oral candidates, reducing urgency around SmartDepot. With the evaluation window closing on October 7 and no public announcements or filings confirming a license, trader consensus heavily favors “No.” A last-minute internal data review could still trigger a deal, though timelines make that unlikely.